BioHarvest FAQ

As of Sept 4, 2024 there were 16.4 Million BHSC shares outstanding, with 37.9 % Insider Ownership.

BioHarvest Sciences is a publicly listed company, listed on the Nasdaq Global Market under the symbol “BHST”.

BioHarvest is also listed in Canada on the Canadian Securities Exchange under the symbol “BHSC”.   

In Europe, BioHarvest trades on the Deutsche Boerse Frankfurt Exchange under the symbol “8MV”  

All shares purchased in any of these markets are for the same public shares of Bioharvest, all of which are issued via the Canadian Securities listing.  

As an early-stage biotechnology company, additional financings may be undertaken to fund expansion and development. These investment opportunities will be announced via news release.   

All investor-related questions are welcome, and we will respond within 24 hours. Contact our Investor Relations team at info@bioharvest.com.  

Yes, it can. In February 2024, Bioharvest announced that it had signed two contracts with industrial partners to produce plant based molecules, and that this would be done under the new Contract Development and Manufacturing Organization (CDMO) business unit. This new business unit allows pharmaceutical, cosmeceutical, nutraceutical and nutrition industry leaders the opportunity to partner with BioHarvest to utilize its Botanical Synthesis Process technology through a typical CDMO contracting model. This proprietary process technology enables the development and manufacturing of patentable plant based small molecules, complex molecules,  and unique compositions which include both small and complex molecules.

Botanical Synthesis is non-GMO. Our process enables us to elicit (increase concentrations of) molecules containing active plant ingredients that are produced by the plant cells. We identify the cells that are best able to produce the desired phytochemicals, and then those cells become the cell bank for future harvests. Using this method, we are able to mirror, multiply, and magnify,  active phytonutrients, and no genetic modification is involved.  

If you have any questions about our technology or commercialization plans, contact us at info@bioharvest.com. All investor-related queries will be answered within 24 hours.  

If you are an investor who would like to join an informal Q+A Zoom call with a small group of other investors and CEO Ilan Sobel, we host a Zoom “Coffee With Ilan” Q+A weekly, at 11am PST each Wednesday PST. Contact info@bioharvest.com to book your spot in an upcoming session.  

Subscribe to our social media channels for a steady stream of corporate information, or subscribe to our News Alert list to receive our biggest news updates directly from us.  

We strive to be as transparent and communicative as is possible for a public company. BioHarvest hosts interactive shareholder webinars quarterly, and we welcome all comments and questions from our shareholder partners as we push forward on our mission to improve human wellness while doing no harm to the world.  

Our technology platform is capable of growing any type of plant cells. We prioritize our products in order to optimize both Human Utility Value and shareholder return. Our current product pipeline is focused on grape, olive, and pomegranate formulations. While our Research and Development team is actively reviewing other cell types, our current focus on near term profitability is to prioritize the development of products that include VINIA. The first “VINIA Inside” product released in December 2023 was our Premium Medium roast and decaffeinated VINIA functional coffees. The future product development pipeline includes additional Hot Beverage products such as Nespresso compatible pods and teas, a performance hydration product, and skin formulations.  

We released a line of new Tea products in December 2024, including Green , Cranberry Hibiscus, Green Matcha, and English Breakfast black Teas.

We are actively testing new horizons for our Red Grape Cells, olive cells, and pomegranate cells unique compositions and these are expected to produce new options for future products.  

  • VINIA revenues grew from $5.5M in 2022, then to $12.7M in 2023, and are now trending to a 12 month revenue rate of $24Million+, with Q3 2024 revenues cresting $6.5 Million USD for the first time.
  • VINIA revenues continue to grow through a combination of increasing production, adding Product SKUs, and by executing on campaigns with wider reach. We are also working to expand demographic appeal, such as addressing younger consumers looking for healthy options to improve energy levels. In addition to the December 2023 launch of our first “VINIA inside” Hot Beverages, we released a full line of “VINIA Inside” Tea products in November 2024, and we are working to expand into new markets. Click here to read the announcement of our license to sell VINIA into Canada.

  •     VINIA is marketed through a highly optimized VINIA sales program that includes TV, a sophisticated Direct to Consumer digital marketing program, and a growing Direct to Doctor network.

    In June 2024, BioHarvest announced that May 2024 was the first month where VINIA sales topped $2Million USD. 

    In that release, CEO Ilan Sobel outlined the growth strategy for VINIA:

“We are committed to create products with superior efficacy based on superior science, and VINIA’s subscriber growth rate and industry leading 4.8 out of 5 review rating is testament to the power of real science,” said Ilan Sobel, Chief Executive Officer of BioHarvest Sciences. “Our record sales in May 2024 validate the power of our recurring revenue model and our confidence in the sustainable growth capabilities of our direct marketing and sales platform. As we expand our Direct-to-Consumer Products strategy, we see multiple opportunities to further expand our revenue by adding new ‘VINIA Inside’ delivery systems. This includes the upcoming completion of our Hot Beverage Strategy for 2024, where we will introduce a range of teas, featuring Breakfast and Green teas. We are also formulating and testing VINIA® Hydration Powder and Skincare products, which will be the Company’s first Sports Performance and Skin Health products.

“We are layering in several new marketing programs in early June, which taken in tandem with additional VINIA® products in the near-term product pipeline, and with the ramp-up of our CDMO Services Business Unit, positions us for robust and sustainable growth in the quarters ahead. Looking to this second quarter of 2024, we continue to expect revenues to be in the range of $5.7-6.0 million. I look forward to continuing our operational execution in the months ahead as we strive towards a Nasdaq listing by year-end,” concluded Sobel.